TNF and inflammatory bowel disease: Patients were divided into three groups: (1) IBD patients receiving anti-TNFα monotherapy (n = 57); (2) patients receiving anti-TNFα therapy in combination with thiopurines (n = 53); and (3) patients receiving thiopurine monotherapy (n = 38).